On September 26, 2013, Chan, Bryan; Estrada, Anthony; Shore, Daniel; Sweeney, Zachary published a patent.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine The title of the patent was Preparation of pyrazolopyridines for treatment of Parkinsons disease. And the patent contained the following:
The title compounds I or II [R1 = (un)substituted alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl, cycloalkyl; for I: 1-3 of X1-X4 = N, and the remainder are each CR2; for II: X4 = C or N, and 1-2 of X1-X3 = N and NR8, and the remainder = CR2, such that X1-X4 and N form a heteroaryl; R2 = H, alkyl, CN, halo, etc.; R8 = H, (un)substituted alkyl; with the proviso], useful for the prevention or treatment of a disorder caused by, associated with or accompanied by abnormal kinase activity, preferably abnormal LRRK2 activity, were prepared E.g., a multi-step synthesis of III, starting from 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine, was described. Exemplified compounds I and II were tested for their LRRK2 activity (data given). Pharmaceutical compositions comprising compound I or II, alone or in combination with other therapeutic agent, were disclosed. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine
The Article related to pyrazolopyridine preparation lrrk2 inhibitor antiparkinsonian combination chemotherapy, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia